The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy

The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy

The optimal sequence of chemoradiotherapy with immunotherapy is still not established. The patient’s immune status may play a role in determining this order. We aim to determine the kinetics of a multi-potential haemopoietic factor FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiothera...

Full description

Bibliographic Details
Main Authors: Łukasz Kuncman, Magdalena Orzechowska, Konrad Stawiski, Michał Masłowski, Magdalena Ciążyńska, Leszek Gottwald, Tomasz Milecki, Jacek Fijuth
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
chemoradiotherapy
immunotherapy
radiotherapy
FMS-related tyrosine kinase 3 ligand (Flt-3L)
dendric cells
active bone marrow
Online Access:https://www.mdpi.com/2072-6694/14/16/3844

Internet

https://www.mdpi.com/2072-6694/14/16/3844

Similar Items